Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19416971 | 0.89 | TRPV1 (0.41) | TRPV1POLBCYP3A4CYP3A5 | |
| SCHEMBL13977891 | 0.89 | TRPV1 (0.41) | TRPV1POLB | |
| SCHEMBL13977336 | 0.88 | NAMPT (0.42) | TRPV1POLBMEN1KMT2A | |
| SCHEMBL4282943 | 0.87 | CCR1 (0.42) | POLBMEN1KMT2AJAK2JAK1 | |
| SCHEMBL13977509 | 0.87 | TRPV1 (0.42) | TRPV1POLBJAK2JAK1 | |
| SCHEMBL13977512 | 0.86 | GPR119 (0.43) | TRPV1JAK2JAK1 | |
| SCHEMBL3804357 | 0.86 | TRPV1 (0.43) | TRPV1 | |
| SCHEMBL12073206 | 0.84 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL9999453 | 0.84 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL4553743 | 0.83 | TRPV1 (0.62) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2604598-B1 | TRPV1 antagonists and uses thereof | PURDUE PHARMA LP (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011162409-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011162409-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| WO-2008132600-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885POLB 4876/4885MEN1 4805/4885 |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885POLB 4870/4885MEN1 4830/4885 |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885POLB 4870/4885MEN1 4830/4885 |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885POLB 4876/4885MEN1 4805/4885 |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885POLB 4876/4885MEN1 4805/4885 |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885POLB 4876/4885MEN1 4805/4885 |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885POLB 4873/4885MEN1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.